KaloBios Confirms Communications with Majority Shareholder Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Macrocure (MCUR) Ramps Higher
November 20, 2015 10:47 AM ESTMacrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.
... MoreShock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street
November 19, 2015 1:36 PM ESTThe stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.
$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.
You see, just... More
KaloBios Pharma (KBIO) In Discussions with Shkreli Group About Continuing Operations
November 19, 2015 6:22 AM ESTKaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding... More
